|Scientific Subdivisions | The Journal of Molecular Diagnostics
Contact AMP | Sign In | Join / Renew | Go To CHAMP
AMP has announced a new report that examines how sophisticated technology advancements are being implemented to improve diagnosis and optimize treatment selection for multiple invasive, opportunistic and often deadly infectious diseases. The manuscript titled "Emerging and Future Applications of MALDI-TOF Mass Spectrometry in the Clinical Microbiology Laboratory: A Report of the Association for Molecular Pathology" has been released online ahead of publication in the November 2016 issue of The Journal of Molecular Diagnostics.
AMP has a
AMP recently participated in two events designed to help educate lawmakers and congressional staff about laboratory developed procedures (LDPs) and the vital role they play in precision medicine and patient care. Both the U.S. Senate Committee on Health, Education, Labor & Pensions (HELP) Hearing and the Co-hosted Congressional Briefing provided bipartisan forums for AMP leaders to discuss how LDPs are currently designed, validated, regulated, and used in a variety of clinical settings.
Read the Press Release
Eric Lander, PhD, President and Founding Director of the Broad Institute of MIT and Harvard, and Professor of Biology at MIT and Professor of Systems Biology at Harvard Medical School, has earned this year's Award for Excellence in Molecular Diagnostics for his countless contributions to the field. The award will be presented at the AMP 2016 Annual Meeting on November 10, 2016 in Charlotte, N.C. Following the award presentation, Dr. Lander will deliver a special lecture on his 35-year journey uncovering insights to benefit human health.
Read the Press Release
A new report in The Journal of Molecular Diagnostics recognizes the value of testing procedures and promotes paradigm corrections to drive widespread adoption of a more proactive, patient-centered approach to modern healthcare.
View the News Release
View the Report (AMP Reports are free to members and non-members!)
The Association for Molecular Pathology (AMP) today announced the results of its 2016 Leadership Elections. AMP is an organization driven by the dedication of its volunteers and looks forward to working with these newly elected leaders.
The Association for Molecular Pathology (AMP) today announced that it looks forward to working with the U.S. Food and Drug Administration (FDA) to determine the best adaptive approach to regulating Next-Generation Sequencing (NGS) tests. AMP plans on submitting formal comments to the two new draft guidance documents released on July 6th, 2016.
Association for Molecular Pathology (AMP) in partnership with the College of American Pathologists (CAP) and the International Association for the Study of Lung Cancer (IASLC) is pleased to announce a public open comment period for draft recommendations developed during the update and revision of the evidence-based recommendations originally published in Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the CAP, the IASLC, and the AMP
Open Comment Period CLOSED August 2nd. Look for updates on this project in the coming months!
AMP is now accepting registrations and housing reservations for the Annual Meeting!
April 18, 2016: The May 2016 issue of The ChAMPion spans topics from Zika to the recent JMD publication on the results of AMP's microcosting project. Charles E. Hill, MD, PhD, updates membership on the development of Zika LDPs and the importance role community diagnostics will play as mosquito season arrives in the U.S.
Click here to read more
Get a glimpse of AMP's recent work in education, innovation, and advocacy for molecular diagnostics.
Hot off the presses is the first edition of The ChAMPion Newsletter! The ChAMPion aims to better educate members on rapidly evolving public policy issues affecting molecular pathology. Check out the link to the first issue below, where you can read about recent AMP advocacy news including AMP's response to FDA's report on oversight of LDPs; Common Rule NPRM; Genetic Information Nondiscrimination Act (GINA); and two upcoming FDA workshops.
View The ChAMPion
AMP is pleased to endorse the CPIC sponsored draft manuscript Term Standardization for Clinical Pharmacogenetic Test Results: Alleles and Phenotypes. CPIC has assembled an international workgroup, utilized a Delphi process to develop their recommendations, and sought feedback from a number of professional organizations. We are confident that our members' expertise as molecular pathologists can contribute valuable insight and foundations upon which this and other CPIC projects may benefit.